Related Experiment Videos
Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions
Abstract:
Biogenesis of tetrahydrofolate cofactors essential for bacterial growth and survival is blocked by sulfamethoxazole-trimethoprim. An intravenous form of the antimicrobial combination has recently been approved for the treatment of acute, symptomatic, bacterial pyelonephritis, recurrent urinary tract infections, shigellosis, and Pneumocystis carinii pneumonia. Intravenous sulfamethoxazole-trimethoprim has emerged as an invaluable agent for the management of selected infections, including bacterial meningitis and Salmonella bacteremia, where limited therapeutic alternatives exist. In addition, co-administration of intravenous sulfamethoxazole-trimethoprim with a carboxypenicillin provides an empiric treatment for the infected granulocytopenic patient that compares favorably with standard combinations. Adverse events unique to the intravenous form of the drug consist of phlebitis and fluid imbalances. Fluid overload results from the relatively large volumes of 5% dextrose solution required as diluent.
Insights
Sulfamethoxazole-trimethoprim, an essential antimicrobial, blocks bacterial tetrahydrofolate cofactor synthesis. Its intravenous form is approved for treating serious infections like pyelonephritis and pneumonia, offering a vital therapeutic option.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Sulfamethoxazole-trimethoprim inhibits bacterial tetrahydrofolate cofactor biogenesis, crucial for growth.
- An intravenous formulation of this antimicrobial combination has been developed.
Purpose of the Study:
- To review the clinical applications and adverse events of intravenous sulfamethoxazole-trimethoprim.
- To highlight its role in treating specific bacterial infections where alternatives are limited.
Main Methods:
- Literature review of clinical studies and approvals for intravenous sulfamethoxazole-trimethoprim.
- Analysis of its efficacy in treating pyelonephritis, urinary tract infections, shigellosis, Pneumocystis carinii pneumonia, bacterial meningitis, and Salmonella bacteremia.
- Evaluation of its use in empiric treatment for infected granulocytopenic patients.
Main Results:
- Intravenous sulfamethoxazole-trimethoprim is approved for acute pyelonephritis, recurrent UTIs, shigellosis, and P. carinii pneumonia.
- It is valuable for bacterial meningitis and Salmonella bacteremia, offering treatment options when others are scarce.
- Combination therapy with carboxypenicillin shows favorable results for infected granulocytopenic patients.
Conclusions:
- Intravenous sulfamethoxazole-trimethoprim is an important antimicrobial for specific severe bacterial infections.
- Potential adverse events include phlebitis and fluid imbalances, particularly fluid overload due to diluent volume.
- Careful administration and monitoring are necessary to maximize benefits and minimize risks.